Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Inclusion criteria

• Patients 18 years or older with underlying diagnosis of metastatic colorectal cancer or head and neck squamous cell carcinoma including newly diagnosed patient
• Patients must provide written informed consent to participate in the study
• Anticipated initiation of cetuximab treatment with or without additional chemotherapy.
• Able to self-administer topical interventions or provide for another person to apply the topical interventions

Exclusion criteria

• Females of childbearing potential who are pregnant or nursing
• Patients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel product
• Patients with pre-existing dermatologic condition affecting the face and chest that would impair assessment of papulopustular rash including dense and/or long facial hair (per investigator discretion)
• Patients currently using prescription and/or over-the-counter topical medications to the face and/or chest who are unwilling to discontinue use during the trial intervention period (day 0 ± 2 days through day 28 ± 2 days)
• Previous or concurrent radiation therapy to head, neck, and chest (i.e. application sites only)
• Previous therapy with cetuximab within 6 months of consent